Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 4

1(100.0%)

1Total

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT06687109Recruiting

A Prospective Total Joint Surgery Registry to Monitor Short- and Long-Term Clinical Outcomes

Role: lead

NCT01359527Completed

Dual Energy X-ray Absorptiometry (DXA) Comparison Hip Resurfacing Versus Total Hip Arthroplasty (THA)

Role: lead

NCT01359540Completed

Femoral Remodeling Following Total Hip Arthroplasty With OMNI Apex Modular™ and OMNI Apex ARC™ Stem Compared to Competitive Designs

Role: lead

NCT01267279Phase 4Completed

Effect of Zoledronic Acid on Femoral Bone Loss Following Total Hip Arthroplasty

Role: lead

NCT01367938Completed

Clinical Outcomes With Omni Apex Ultracongruent Knee System

Role: lead

NCT01367925Completed

Stryker Triathlon® Cruciate Substituting vs. Posterior Stabilized Outcomes Study

Role: lead

All 6 trials loaded